You are here

Four-Strain Flu Vaccine Gets FDA Nod

Vaccine includes two B strains instead of one (June 10)

The FDA has approved Fluzone Quadrivalent vaccine (Sanofi Pasteur). The four-strain influenza vaccine is licensed for use in children (6 months of age and older), adolescents, and adults.

The 2013–2014 influenza season will be the first in which quadrivalent influenza vaccines will be available in the U.S. Until this year, seasonal influenza vaccines included only one B strain. The Fluzone Quadrivalent vaccine includes two A strains and two B strains.

Epidemics of influenza B occur every 2 to 4 years in all age groups. Influenza B is a common cause of influenza-related morbidity and mortality in children and has been associated with pneumonia and other respiratory illnesses, nervous system disease, muscle pain and inflammation, and other complications. In recent years, up to 44% of influenza-associated deaths in children and adolescents 18 years of age and younger were due to influenza B.

Each winter the strains for the seasonal influenza vaccines are selected from the influenza strains anticipated to circulate in the Northern Hemisphere during the approaching influenza season. Seasonal influenza vaccines in the U.S. contained only two strains (one strain of type A influenza and one strain of type B influenza) until 1978, when the decision was made to incorporate a second type A influenza strain to help provide protection against both A strains that were co-circulating.

For the past 35 years, influenza vaccines have been trivalent to help protect against three strains of influenza virus: type A(H1N1), type A(H3N2), and one type B. However, since the 2001–2002 season, two distinct influenza B types (the Victoria and Yamagata lineages) have co-circulated with varying prevalence, making it difficult to predict the next season’s dominant B lineage strain. In six of the past 12 seasons, the dominant circulating B strain was from the B-lineage not selected for the vaccine.

The Fluzone Quadrivalent vaccine will be available to healthcare providers in the U.S. for the 2013–2014 influenza season in prefilled syringes and single-dose vials for intramuscular administration.

Source: Sanofi Pasteur; June 10, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs